MBX Biosciences, Inc. Common Stock (MBX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Peter Kent Hawryluk	Chief Executive Officer, President & Director	992,775	1969
Steven L. Hoerter	Executive Chairperson	40,477	1971
Salomon Azoulay	Chief Medical Officer	734,944	1958
Mark R. Soued	Chief Commercial Officer	0	N/A
Karen Basbaum	Chief Business Officer	0	N/A
Andreas Moraitis	Senior Vice President of Clinical Development	0	N/A
Michelle Graham	Chief Human Resources Officer	0	1967
Pete De Spain	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
Chatan Charan	Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls	0	N/A
John W. Smither	Interim Chief Financial Officer	0	1953
Michael A. Dorato DABT	Sr. Vice President of Discovery & Non-Clinical Development	0	N/A
Mark Hope	Senior Vice President of Regulatory & Quality	0	N/A

Name

Title

Pay

Year Born

Peter Kent Hawryluk

Chief Executive Officer, President & Director

992,775

1969

Steven L. Hoerter

Executive Chairperson

40,477

1971

Salomon Azoulay

Chief Medical Officer

734,944

1958

Mark R. Soued

Chief Commercial Officer

N/A

Karen Basbaum

Chief Business Officer

N/A

Andreas Moraitis

Senior Vice President of Clinical Development

N/A

Michelle Graham

Chief Human Resources Officer

1967

Pete De Spain

Senior Vice President of Investor Relations & Corporate Communications

N/A

Chatan Charan

Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls

N/A

John W. Smither

Interim Chief Financial Officer

1953

Michael A. Dorato DABT

Sr. Vice President of Discovery & Non-Clinical Development

N/A

Mark Hope

Senior Vice President of Regulatory & Quality

N/A

Description

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.